Peter Ellmark

10PUBLICATIONS
45CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene expression (incl. microarray and other genome-wide approaches)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Sep 10, 2025
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade.

Hampus Andersson, Ida Uddbäck, Tova Hermodsson

|Jan 23, 2025
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.

Ana Carneiro, Amanda Hahn, Peter Ellmark

|Jun 19, 2024
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes.

Viktor Sincic, Ken F Arlenhold, Sarah Richtmann

|May 20, 2024
Next-generation CD40 agonists for cancer immunotherapy.

Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson

|Oct 13, 2023
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody.

Hampus Andersson, Aastha Sobti, David Gomez Jimenez

|Oct 05, 2023
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.

Karin Enell Smith, Sara Fritzell, Anneli Nilsson

Pageof 2

Frequent Collaborators

3 joint publications

Laura von Schantz

3 joint publications

Sara Fritzell

2 joint publications

Anna Säll

2 joint publications

Anneli Nilsson